A Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab) in the Therapy of Moderate-to-Severe Allergic Asthma

Publisher： Bentham Science Publishers

E-ISSN： 2212-2710|1|3|225-231

ISSN： 1872-213X

Source： Recent Patents on Inflammation & Allergy Drug Discovery, Vol.1, Iss.3, 2007-01, pp. : 225-231

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Relevance of IgE in the Pathogenesis of Allergy: The Effect of an Anti-IgE Drug in Asthma and Other Diseases

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 1, Iss. 2, 2007-06 ,pp. : 151-164

Bentham Science Publishers

Access to resources Recommend Favorite

Effect of Tetracyclines on IgE Allergic Responses and Asthma

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 5, Iss. 3, 2011-09 ,pp. : 221-228

Bentham Science Publishers

Access to resources Recommend Favorite

Omalizumab: Not Only For Asthma

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 2, Iss. 3, 2008-11 ,pp. : 191-201

Bentham Science Publishers

Access to resources Recommend Favorite

Experimental Approaches Towards Allergic Asthma Therapy-Murine Asthma Models

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 4, Iss. 1, 2010-01 ,pp. : 37-53

Bentham Science Publishers

Access to resources Recommend Favorite

Omalizumab for Asthma: Indications, Off-Label Uses and Future Directions

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 4, Iss. 3, 2010-11 ,pp. : 183-192

Bentham Science Publishers

Access to resources Recommend Favorite